Institutional Review Boards and Humanitarian Use Device (HUD)

Presented by Fabienne Santel, MD

Division of Bioresearch Monitoring
Office of Compliance
Center for Devices and Radiological Health
Food and Drug Administration
Learning objectives

- Define Humanitarian Use Device
- Describe FDA’s approval
- Identify the HDE-holder responsibilities
- Identify the physician responsibilities
- Describe the IRB responsibilities
Topics

- Humanitarian Use Device (HUD)
- Humanitarian Device Exemption (HDE)
- FDA review
- HDE-holder responsibilities
- Physician responsibilities
- IRB responsibilities
- FDA concerns
Humanitarian Use Device (HUD)

- HUD definition
  - Title 21 CFR 814.3(n)
  - A device intended to benefit patients in the treatment or diagnosis of a disease or condition affecting fewer than 4,000 individuals in the US per year
Office of Orphan Products Development designates a device as a Humanitarian Use Device (HUD)
  – Verifies that the device is designed to treat or diagnose a disease or condition following the parameters in the definition
  – Reviews a description of the device
  – Reviews a description of the rare disease or condition
Humanitarian Device Exemption (HDE)

HDE Definition

- Title 21 CFR 814.2
- A premarket approval application submitted to FDA seeking a Humanitarian Device Exemption from the effectiveness requirements of sections 514 and 515 of the Food, Drug, Cosmetic Act.
Humanitarian Device Exemption
Application to FDA

- FDA approval of HDE application
  - HUD does not pose unreasonable risk of injury to patients
  - That the probable benefit outweighs risk of injury from its use
Humanitarian Device Exemption Application to FDA

- FDA approval of the HDE
  - HDE label states
    - The device is a Humanitarian Use Device
    - The device, to treat or diagnose a specific disease or condition, is authorized by federal law
    - The effectiveness of this device for this use has not been demonstrated
Humanitarian Device Exemption Application to FDA

- FDA approval of a HDE application allows the HUD to be marketed
The HDE-holder must
- Have both HUD designation and approved HDE from FDA before device is shipped to institutions with Institutional Review Board (IRB) oversight
HDE-Holder

- The HDE-holder is responsible for ensuring initial and continuing IRB review
- The HDE-holder may wish to enforce this by not shipping HUDs to institutions until after receiving documentation of IRB approval
The HDE-holder is responsible for ensuring:

- the HUD is not administered to or implanted in a patient prior to obtaining IRB approval at the health care facility.
The HDE-holder must
- Maintain IRB correspondence
- Report clinical experience, including safety information, to FDA in annual reports
Physician Responsibilities

- Obtain IRB approval and continuing approval
- Follow IRB requirements
- Give patients HUD information packet
- Report serious adverse events and deaths using the Medical Device Reporting system at 21 CFR 803.
IRB initial review of HUDs

- Use approval criteria at 21 CFR 56.111
  - Consideration of the patient’s need for the HUD
  - Likelihood that device is appropriate for the patient’s condition or disease state
IRB continuing review of HUDs

- Follow written procedures for continuing review
  - Convened meeting, or
  - Expedited review is acceptable because it is an approved device
IRB review of HUDs

- An IRB may approve the use of the HUD
  - In general
  - For groups of HUD patients that meet certain criteria
  - Under a HUD treatment protocol, or
  - On a case-by-case HUD basis
IRB limitations on HUD use based on:

- One or more measures of disease progression
- Prior use and failure of alternate treatment modalities
IRB limitations on HUDs use based on

- Reporting requirements to IRB or IRB Chair
- Appropriate follow-up precautions and evaluations
- Any other criteria it determines appropriate
IRB withdrawal of approval

- IRBs must be constituted and act in accordance with the agency’s regulations and withdraw approval for:
  - Failure to follow IRB or FDA requirements
  - Unexpected serious harm or death
- Questions to ask at continuing review
  - Reporting serious adverse events or deaths
  - Following IRB conditions of approval or limitations
Medical Device Reporting (MDR) and Humanitarian Use Devices

- Applies to all FDA approved devices
- Serious adverse events and deaths must be reported to FDA and the IRB using the Medical Device Reporting system at 21 CFR 803
- HDE-holders and IRBs should ensure that physicians know about this requirement
FDA Concerns

- Off label use of an HUD
  - IRB should ensure that physicians are made aware of any restrictions or limitations of off-label use at the time of initial review.
  - FDA recommends informed consent and reasonable patient protections measures
    - Monitoring and considering the specific needs of the patient and limited information about risks and effectiveness of the HUD
  - Summary report to IRB and HDE-holder following the use
FDA Concerns

- Research for HDE-approved indication
  - No Investigational Device Exemption (IDE) required
  - IRB review and informed consent recommended

- Research outside approved indication
  - Requires an (IDE) 21 CFR 812
  - IRB review and informed consent required
References

- Regulation
  - 21 CFR 814 Subpart H
  - 21 CFR 56 Institutional Review Boards
  - 21 CFR 803 Medical Device Reporting

- Guidance
  www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhDE/HDEInformation.cfm
  - List of all HUDs
  - Frequently asked questions and answers
Summary

- Humanitarian Use Device and Humanitarian Device Exemption
- FDA’s approval criteria
- HDE-holder responsibilities
- Physician responsibilities
- IRB responsibilities